U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07587879) titled 'Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors' on April 27.
Brief Summary: PMC2129G12 is an investigational intratumorally administered messenger RNA-lipid nanoparticle (mRNA-LNP) immunotherapy designed to enable localized, transient expression of a humanized EpCAM-targeted CD3-engaging bispecific antibody together with the immunostimulatory cytokines to kill tumors by recruited immune T cells.
Study Start Date: Jan. 01, 2027
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
GENETIC: mRNA-LNP
intratumoral mRNA-LNP administration
Recruitment Status: NOT_...